How Glucose–Fructose-Laden Drinks: Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, with metastatic disease accounting for the majority of fatalities. While genetics and lifestyle factors have long been recognized as contributors to CRC risk, emerging research highlights the significant role of diet not only in the development of cancer but also in its progression. Recent findings from the University of Texas MD Anderson Cancer Center suggest that sugar-sweetened beverages (SSBs), specifically those containing a mix of glucose and fructose, may actively fuel the spread of colorectal cancer.
The study, published in Nature Metabolism, identifies a critical molecular player, the SORD enzyme, which converts sorbitol to fructose. This enzyme appears to drive CRC metastasis, particularly to the liver, in preclinical models. The implications are significant: routine consumption of sugary drinks, including soda, energy drinks, and fruit juices, may directly influence cancer behavior, highlighting the importance of dietary interventions for CRC patients.
The Role of Glucose and Fructose in CRC Progression
Sugar-Sweetened Beverages and Cancer Cell Motility
The MD Anderson study demonstrates that exposure to a combination of glucose and fructose, rather than either sugar alone, significantly enhances cancer cell motility and promotes metastasis in colorectal cancer. In preclinical models, this sugar mix was shown to drive liver metastasis by altering key metabolic pathways within cancer cells.
SORD Enzyme: A Key Driver of Metastasis
The study highlights SORD (sorbitol dehydrogenase) as a critical enzyme that converts sorbitol to fructose and boosts glucose metabolism. Activation of SORD by the glucose-fructose mix triggers downstream cholesterol pathways, which in turn promote CRC cell motility. Notably, inhibition or removal of SORD in the models significantly suppressed cancer cell migration even when the sugar mix was present, underscoring SORD’s role as a potential therapeutic target.
Read about: Chemotherapy and Immunotherapy: Exploring Combined Treatment Approaches Explained by Dr. Pooja Babbar
Potential Therapeutic Approaches
Targeting the SORD Enzyme
The study identifies SORD as a promising therapeutic target. By inhibiting SORD, it may be possible to reduce CRC metastasis and block the metabolic pathways that drive cancer spread.
Repurposing Statins
Since the glucose-fructose mix activates downstream cholesterol synthesis via the mevalonate pathway, statins—which inhibit cholesterol synthesis—could serve as a potential adjunct treatment. Statins may be particularly beneficial for patients with high SORD expression and elevated sugar intake, providing a rationale for future clinical trials.
Future Directions
While these findings are currently limited to preclinical models, they open new avenues for research. Prospective studies in humans are needed to evaluate the interplay between SORD expression, dietary sugar consumption, and the efficacy of interventions such as statins. This research emphasizes the importance of personalized approaches to CRC management, integrating both diet and molecular targets.
Also read: Indian Rupee Hits All-Time Low of 88.49 Against US Dollar Amid Weak Asian Cues
FAQ’s
1. How do glucose-fructose drinks promote colorectal cancer metastasis?
Research shows that a combination of glucose and fructose fuels cancer cell motility through metabolic pathways. The sugars elevate the NAD⁺/NADH ratio, accelerate glycolysis, and activate the mevalonate pathway, which enhances metastatic potential.
